Approximately 60%–80% of ALK + ALCL patients treated with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) show long-term survival, and CHOP was the standard of care for ALK + ALCL [2–5]. The gene discussed is ALK; the disease is anaplastic large cell lymphoma.